EXAS claims Cologuard 2.0 superiority_to_existing Cologuard, but Evaluate Vantage says lack of improved sensitivity for pre-cancerous lesions is disappointing: https://finance.yahoo.com/news/next-generation-cologuard-test-demonstrates-200500387.html https://www.evaluate.com/vantage/articles/news/trial-results/exacts-next-gen-cancer-screen-beats-original The new version of Cologuard won’t be commercially available until 2024.